<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MDA - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/empathogens/">Empathogens</a> ‚Üí <span>MDA</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üåà MDA</h1>
        <h2 class="chemical-name">3,4-Methylenedioxyamphetamine</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="MDA" 
                data-category="Empathogens" 
                data-chemical="3,4-Methylenedioxyamphetamine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>Sally</span> ‚Ä¢ <span>Sass</span> ‚Ä¢ <span>MDA</span> ‚Ä¢ <span>Love Drug</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Tenamfetamine</span> ‚Ä¢ <span>The Love Pill</span> ‚Ä¢ <span>Mellow Drug of America</span>
            </div>
            <div class="name-category">
              <h4>Historical Names</h4>
              <span>R-(-)-MDA</span> ‚Ä¢ <span>3,4-MDA</span> ‚Ä¢ <span>Methylenedioxyamphetamine</span>
            </div>
            <div class="name-category">
              <h4>Chemical Designations</h4>
              <span>MDA-HCl</span> ‚Ä¢ <span>MDMA precursor</span> ‚Ä¢ <span>MDMA metabolite</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category empathogen">Empathogen</span>
          <span class="category psychedelic">Psychedelic</span>
          <span class="legal-status schedule-1">Schedule I</span>
          <span class="duration long">6-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/mda.jpg" alt="MDA crystals with kaleidoscopic background" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÄH‚ÇÅ‚ÇÉNO‚ÇÇ</p>
            <p>MW: 179.22 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure MDA (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystalline powder, similar to MDMA</li>
            <li><strong>Odor:</strong> Faint chemical smell, less distinctive than MDMA</li>
            <li><strong>Taste:</strong> Bitter and numbing, similar intensity to MDMA</li>
            <li><strong>Solubility:</strong> Highly soluble in water and alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Street Forms</h4>
          <ul>
            <li><strong>Pills/Tablets:</strong> Less common than MDMA pills, various colors and logos</li>
            <li><strong>Powder:</strong> Often sold as "Sally" or "Sass" in capsules</li>
            <li><strong>Crystals:</strong> Chunky crystal form, can range from clear to brownish</li>
            <li><strong>Mixed pills:</strong> Sometimes combined with MDMA in pressed tablets</li>
          </ul>
        </div>
        
        <div class="identification-challenges">
          <h4>‚ö†Ô∏è Identification Challenges</h4>
          <p><strong>MDMA similarity:</strong> Nearly identical appearance to MDMA crystals/powder</p>
          <p><strong>Reagent testing:</strong> Very similar color reactions to MDMA with most reagents</p>
          <p><strong>Effects-based ID:</strong> More psychedelic, longer duration, increased body load</p>
          <p><strong>MDMA metabolite:</strong> MDA is produced when MDMA breaks down in the body</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">40-60mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">60-100mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">100-160mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">160-200mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">200mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Dosage Considerations</h4>
        <ul>
          <li><strong>Longer duration:</strong> 6-8 hours vs MDMA's 4-6 hours</li>
          <li><strong>More potent visually:</strong> Lower doses produce visual effects than MDMA</li>
          <li><strong>Body load increases:</strong> Higher doses bring significant physical discomfort</li>
          <li><strong>No redosing recommended:</strong> Extended duration makes redosing unnecessary</li>
          <li><strong>First time:</strong> Start with 80-100mg to assess sensitivity</li>
          <li><strong>Individual variation:</strong> Wide range of sensitivity between users</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Duration Warning:</strong> MDA's longer duration means commitment to 6-8 hours of effects. Plan accordingly and ensure safe environment.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:00</span>
          <span class="effect">Onset - energy increase, mild visuals beginning</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-4:00</span>
          <span class="effect">Peak - intense empathy, strong visuals, body euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-7:00</span>
          <span class="effect">Plateau - sustained effects, continued visuals</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+7:00-12:00</span>
          <span class="effect">Comedown - gradual decline, potential fatigue</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Positive Effects</h4>
          <ul>
            <li>Deep emotional empathy and connection</li>
            <li>Colorful visual hallucinations and patterns</li>
            <li>Enhanced music appreciation and synesthesia</li>
            <li>Intense euphoria and wellbeing</li>
            <li>Increased energy and alertness</li>
            <li>Enhanced tactile sensations</li>
            <li>Spiritual and introspective experiences</li>
            <li>Enhanced emotional processing</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects</h4>
          <ul>
            <li>Significant body load and tension</li>
            <li>Jaw clenching and teeth grinding (bruxism)</li>
            <li>Nausea, especially during onset</li>
            <li>Hyperthermia and sweating</li>
            <li>Anxiety during peak effects</li>
            <li>Fatigue and emotional depletion afterward</li>
            <li>Difficulty sleeping post-experience</li>
            <li>Potential for overwhelming experiences</li>
          </ul>
        </div>
      </div>

      <div class="mda-characteristics">
        <h4>üåÄ MDA's Unique Profile</h4>
        <div class="characteristic-comparison">
          <div class="comparison-item">
            <h5>vs. MDMA</h5>
            <ul>
              <li><strong>More psychedelic:</strong> Significant visual hallucinations</li>
              <li><strong>Longer lasting:</strong> 6-8 hours vs 4-6 hours</li>
              <li><strong>More introspective:</strong> Deeper internal experience</li>
              <li><strong>Higher body load:</strong> More physical discomfort</li>
              <li><strong>Less social:</strong> More inward-focused than MDMA</li>
              <li><strong>More stimulating:</strong> Greater amphetamine-like effects</li>
            </ul>
          </div>
          <div class="comparison-item">
            <h5>Psychedelic Elements</h5>
            <ul>
              <li><strong>Closed-eye visuals:</strong> Geometric patterns and imagery</li>
              <li><strong>Open-eye visuals:</strong> Color enhancement, pattern recognition</li>
              <li><strong>Thought loops:</strong> Repetitive thinking patterns</li>
              <li><strong>Time distortion:</strong> Altered perception of time passage</li>
              <li><strong>Synesthesia:</strong> Cross-sensory experiences (hearing colors)</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>MDA acts as a potent triple monoamine releasing agent similar to MDMA, but with greater selectivity for serotonin release and stronger 5-HT2A receptor activation. This combination produces both empathogenic and psychedelic effects, bridging the gap between stimulants and classical psychedelics.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (5-HT transporter)</strong></span>
            <span class="affinity">Very high affinity</span>
            <span class="function">Primary empathogenic effects, emotional openness</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT2A receptor</strong></span>
            <span class="affinity">Moderate agonist activity</span>
            <span class="function">Visual hallucinations, psychedelic effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (NE transporter)</strong></span>
            <span class="affinity">High affinity</span>
            <span class="function">Stimulant effects, increased energy, body load</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (DA transporter)</strong></span>
            <span class="affinity">Moderate affinity</span>
            <span class="function">Euphoria, reward, motivation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>5-HT1A receptor</strong></span>
            <span class="affinity">Partial agonist</span>
            <span class="function">Mood regulation, some anxiolytic effects</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Duration:</strong> 6-8 hours (longer than MDMA due to different metabolism)</p>
          <p><strong>Metabolism:</strong> Hepatic oxidation and conjugation pathways</p>
          <p><strong>Half-life:</strong> Approximately 8-10 hours</p>
          <p><strong>Peak effects:</strong> 2-4 hours after oral administration</p>
          <p><strong>Active metabolites:</strong> 3,4-Dihydroxyamphetamine (DHA) and others</p>
          <p><strong>MDMA relationship:</strong> MDA is also an active metabolite of MDMA</p>
        </div>

        <h4>Neurotoxicity Profile</h4>
        <div class="neurotoxicity-info">
          <p><strong>Serotonin depletion:</strong> Significant 5-HT depletion, potentially greater than MDMA</p>
          <p><strong>Dopamine involvement:</strong> Direct dopaminergic activity may increase neurotoxic risk</p>
          <p><strong>Temperature sensitivity:</strong> Hyperthermia increases neurotoxic potential</p>
          <p><strong>Frequency sensitivity:</strong> Repeated use causes cumulative damage</p>
          <p><strong>Metabolite toxicity:</strong> Some metabolites may contribute to neurotoxic effects</p>
        </div>

        <h4>Pharmacological Distinctions</h4>
        <ul>
          <li><strong>5-HT2A activity:</strong> Stronger psychedelic receptor activation than MDMA</li>
          <li><strong>Longer half-life:</strong> Extended duration due to slower metabolism</li>
          <li><strong>Greater selectivity:</strong> More selective for serotonin vs dopamine release</li>
          <li><strong>Higher potency:</strong> More potent per milligram than MDMA</li>
          <li><strong>Different metabolites:</strong> Unique breakdown products with distinct effects</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Extended duration:</strong> 6-8 hours of intense effects</li>
            <li><strong>High body load:</strong> Significant physical discomfort possible</li>
            <li><strong>Hyperthermia risk:</strong> Dangerous overheating, especially with activity</li>
            <li><strong>Neurotoxicity:</strong> Potentially greater serotonin depletion than MDMA</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Harm Reduction Practices</h4>
          <ul>
            <li>Plan for full 8+ hour experience commitment</li>
            <li>Cool environment essential due to hyperthermia risk</li>
            <li>Magnesium supplementation for jaw clenching</li>
            <li>Antioxidants (ALA, Vitamin C/E) for neuroprotection</li>
            <li>Longer breaks between uses (3+ months minimum)</li>
            <li>Test substances - MDA/MDMA often confused</li>
          </ul>
        </div>
      </div>

      <div class="body-load-management">
        <h4>üèãÔ∏è Managing Body Load</h4>
        <div class="body-load-tips">
          <div class="tip-item">
            <h5>Physical Comfort</h5>
            <ul>
              <li>Comfortable, loose clothing</li>
              <li>Temperature control (cool environment)</li>
              <li>Massage tools or trusted person for back/neck tension</li>
              <li>Stretching and gentle movement</li>
            </ul>
          </div>
          <div class="tip-item">
            <h5>Jaw Clenching</h5>
            <ul>
              <li>Magnesium supplements (200-400mg)</li>
              <li>Sugar-free gum or pacifiers</li>
              <li>Jaw massage and stretching</li>
              <li>Mindful awareness of tension</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Heart conditions, high blood pressure, seizure disorders, psychiatric medications (especially MAOIs/SSRIs), anxiety disorders, or claustrophobia (visual effects can be intense).</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome and hypertensive crisis</li>
            <li><strong>SSRIs/SNRIs:</strong> Serotonin syndrome, blunted effects</li>
            <li><strong>Tramadol:</strong> Increased seizure risk, serotonin syndrome</li>
            <li><strong>DXM:</strong> Serotonin syndrome potential</li>
            <li><strong>Lithium:</strong> Seizure risk with psychedelic activity</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Other stimulants:</strong> Increased cardiovascular strain and hyperthermia</li>
            <li><strong>Alcohol:</strong> Increased neurotoxicity, dehydration, masking of effects</li>
            <li><strong>Cannabis:</strong> May intensify visuals but increase anxiety</li>
            <li><strong>Psychedelics:</strong> Potentially overwhelming combination</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>2C-x compounds:</strong> Both affect serotonin, additive effects</li>
            <li><strong>Tryptamines:</strong> Risk of overwhelming psychedelic experience</li>
            <li><strong>Nitrous oxide:</strong> Risk of falls during visual experiences</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule I</strong> - Illegal to manufacture, possess, or distribute. Same classification as MDMA.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class A</strong> - Up to 7 years for possession, life for supply. Same penalties as MDMA.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá≥üá± Netherlands</h4>
            <p><strong>List I</strong> - Illegal but enforcement similar to MDMA. Testing services available.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 9</strong> - Prohibited substance with same restrictions as MDMA.</p>
          </div>
        </div>
        
        <div class="legal-considerations">
          <h4>‚ö†Ô∏è Legal Considerations</h4>
          <ul>
            <li><strong>MDMA analogue:</strong> Covered under same legal frameworks as MDMA</li>
            <li><strong>Historical precedent:</strong> Was illegal before MDMA in many jurisdictions</li>
            <li><strong>Metabolite status:</strong> Present in body when MDMA is metabolized</li>
            <li><strong>Research restrictions:</strong> Limited legal research due to Schedule I status</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1910</span>
          <p>First synthesized by G. Mannish and W. Jacobson</p>
        </div>
        <div class="history-event">
          <span class="year">1930s</span>
          <p>Early animal studies conducted but therapeutic potential unexplored</p>
        </div>
        <div class="history-event">
          <span class="year">1960s</span>
          <p>Recreational use begins, called "the love drug" before MDMA</p>
        </div>
        <div class="history-event">
          <span class="year">1970</span>
          <p>Scheduled as controlled substance in US (before MDMA)</p>
        </div>
        <div class="history-event">
          <span class="year">1970s-80s</span>
          <p>Used in underground psychotherapy sessions</p>
        </div>
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Discovered as active MDMA metabolite, explains some MDMA effects</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Renewed research interest for both therapeutic and neurotoxicity studies</p>
        </div>
      </div>

      <div class="cultural-context">
        <h4>Cultural Impact</h4>
        <p>MDA was the original "love drug" of the 1960s counterculture, predating MDMA's popularity by over a decade. Often called "Sally" or "Sass" in modern contexts, MDA occupies a unique position as both an empathogen and psychedelic, attracting users seeking MDMA's emotional effects with added visual experiences.</p>
      </div>

      <div class="mdma-relationship">
        <h4>üîÑ The MDMA Connection</h4>
        <p>MDA's relationship with MDMA is complex - it's both a precursor in MDMA synthesis and an active metabolite when MDMA is consumed. Some of MDMA's later effects and next-day experiences may actually be due to MDA metabolite activity. This dual relationship has made MDA both historically significant and scientifically important.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Neurotoxicity Studies</h4>
          <p>Research comparing MDA and MDMA neurotoxicity suggests MDA may cause greater serotonin depletion, important for understanding MDMA metabolite effects.</p>
        </div>
        
        <div class="research-item">
          <h4>Psychedelic Mechanisms</h4>
          <p>Studies examining MDA's 5-HT2A activity help understand how empathogenic and psychedelic effects can combine in a single compound.</p>
        </div>
        
        <div class="research-item">
          <h4>Metabolite Research</h4>
          <p>Investigation into MDA as an MDMA metabolite helps explain MDMA's extended effects and therapeutic timeline.</p>
        </div>
        
        <div class="research-item">
          <h4>Therapeutic Potential</h4>
          <p>Limited research into MDA's potential for therapy, though its longer duration and psychedelic elements present both opportunities and challenges.</p>
        </div>
      </div>

      <div class="research-gaps">
        <h4>Critical Research Needs</h4>
        <ul>
          <li><strong>Comparative neurotoxicity:</strong> Direct comparison with MDMA in human studies</li>
          <li><strong>Therapeutic efficacy:</strong> Controlled studies of therapeutic potential</li>
          <li><strong>Optimal dosing:</strong> Research into therapeutic vs recreational dose ranges</li>
          <li><strong>Long-term effects:</strong> Longitudinal studies of regular users</li>
          <li><strong>Combination effects:</strong> Understanding MDA's role in MDMA experiences</li>
        </ul>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Testing & Identification</h4>
        <ul>
          <li><a href="https://drugsdata.org/">DrugsData.org</a> - Professional analysis service</li>
          <li><a href="https://bunkpolice.com/">The Bunk Police</a> - Reagent test kits</li>
          <li><a href="https://dancesafe.org/">DanceSafe</a> - Harm reduction resources</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction</h4>
        <ul>
          <li><a href="https://rollsafe.org/">RollSafe</a> - MDMA/MDA harm reduction guide</li>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Comprehensive information</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - User experience community</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Information</h4>
        <ul>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and research</li>
          <li><a href="https://reddit.com/r/MDMA">/r/MDMA</a> - Community discussion (includes MDA)</li>
          <li><a href="https://tripsit.me/">TripSit</a> - Real-time support during experiences</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="mda-vs-mdma-summary">
    <h3>üÜö MDA vs MDMA: Quick Comparison</h3>
    <div class="comparison-grid">
      <div class="comparison-aspect">
        <h4>Duration</h4>
        <p><strong>MDA:</strong> 6-8 hours | <strong>MDMA:</strong> 4-6 hours</p>
      </div>
      <div class="comparison-aspect">
        <h4>Visuals</h4>
        <p><strong>MDA:</strong> Significant visual effects | <strong>MDMA:</strong> Minimal visuals</p>
      </div>
      <div class="comparison-aspect">
        <h4>Body Load</h4>
        <p><strong>MDA:</strong> Higher physical tension | <strong>MDMA:</strong> Moderate body load</p>
      </div>
      <div class="comparison-aspect">
        <h4>Social vs Introspective</h4>
        <p><strong>MDA:</strong> More introspective | <strong>MDMA:</strong> More social/empathogenic</p>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>